{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T16:58:49Z","timestamp":1777568329301,"version":"3.51.4"},"reference-count":27,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2012,11,21]],"date-time":"2012-11-21T00:00:00Z","timestamp":1353456000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2013,6]]},"abstract":"<jats:sec>\n                    <jats:title>What's known on the subject? and What does the study add?<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>No cost\u2010effectiveness studies exist in patients after radical cystectomy for the routine use of alvimopan for the prevention of postoperative ileus.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>The present study provides a reasonable estimate of the cost\u2010effectiveness of alvimopan for the prevention of postoperative ileus in the patient after radical cystectomy.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            To determine if the cost of administering alvimopan, to help restore bowel function after abdominal surgery, to all patients undergoing radical cystectomy (\n                            <jats:styled-content style=\"fixed-case\">RC<\/jats:styled-content>\n                            ) is cost prohibitive.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>A cost\u2010effective analysis was conducted from a healthcare payer perspective using a decision\u2010tree model that incorporated direct healthcare costs and probabilities associated with the possible events and outcomes.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            Sensitivity analyses were conducted on the influence of the cost and effectiveness of the drug, the probability of\n                            <jats:styled-content style=\"fixed-case\">POI<\/jats:styled-content>\n                            in\n                            <jats:styled-content style=\"fixed-case\">RC<\/jats:styled-content>\n                            patients, and the extended length of stay (\n                            <jats:styled-content style=\"fixed-case\">LOS<\/jats:styled-content>\n                            ) as a result of\n                            <jats:styled-content style=\"fixed-case\">POI<\/jats:styled-content>\n                            .\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Precision in estimates was determined using probabilistic sensitivity analyses with 5000 Monte\u2010Carlo simulations.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            Under the base case assumption, the additional cost of a patient's\n                            <jats:styled-content style=\"fixed-case\">LOS<\/jats:styled-content>\n                            related to\n                            <jats:styled-content style=\"fixed-case\">POI<\/jats:styled-content>\n                            was $10\u2009246 per person. Under the assumption that 15.6% of patients will have\n                            <jats:styled-content style=\"fixed-case\">POI<\/jats:styled-content>\n                            , the mean cost associated with\n                            <jats:styled-content style=\"fixed-case\">POI<\/jats:styled-content>\n                            in a cohort of patients not treated with alvimopan was $1597 (90% confidence interval [\n                            <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                            ] $1335\u20131875) per patient.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            Conversely, the routine use of alvimopan for all patients undergoing\n                            <jats:styled-content style=\"fixed-case\">RC<\/jats:styled-content>\n                            was associated with a mean\n                            <jats:styled-content style=\"fixed-case\">POI<\/jats:styled-content>\n                            \u2010associated cost of $1495(90%\n                            <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                            $1312\u20131696) per person, which represents the cost of alvimopan ($700 per hospitalisation) and a 50% reduction in the rate of\n                            <jats:styled-content style=\"fixed-case\">POI<\/jats:styled-content>\n                            .\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            Sensitivity analyses revealed that there is a cost savings with the routine use of alvimopan under the following conditions: the\n                            <jats:styled-content style=\"fixed-case\">POI<\/jats:styled-content>\n                            results in extending\n                            <jats:styled-content style=\"fixed-case\">LOS<\/jats:styled-content>\n                            by \u22653.5 days,\n                            <jats:styled-content style=\"fixed-case\">POI<\/jats:styled-content>\n                            occurs in \u226514% of patients undergoing\n                            <jats:styled-content style=\"fixed-case\">RC<\/jats:styled-content>\n                            , or the drug results in a relative risk reduction of \u226544%.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            Routine use of perioperative alvimopan may not be cost prohibitive because of its influence on\n                            <jats:styled-content style=\"fixed-case\">POI<\/jats:styled-content>\n                            rate and associated costs.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            The cost\u2010effectiveness of alvimopan is influenced by the\n                            <jats:styled-content style=\"fixed-case\">POI<\/jats:styled-content>\n                            incidence and the degree to which the drug can decrease the\n                            <jats:styled-content style=\"fixed-case\">LOS<\/jats:styled-content>\n                            .\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1464-410x.2012.11499.x","type":"journal-article","created":{"date-parts":[[2012,11,21]],"date-time":"2012-11-21T15:16:56Z","timestamp":1353511016000},"page":"1054-1060","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Alvimopan for prevention of postoperative paralytic ileus in radical cystectomy patients: a cost\u2010effectiveness analysis"],"prefix":"10.1111","volume":"111","author":[{"given":"William M.","family":"Hilton","sequence":"first","affiliation":[{"name":"University of Texas Health Science Center  San Antonio TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yair","family":"Lotan","sequence":"additional","affiliation":[{"name":"University of Texas Southwestern Medical Center  Dallas TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dipen J.","family":"Parekh","sequence":"additional","affiliation":[{"name":"University of Texas Health Science Center  San Antonio TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph W.","family":"Basler","sequence":"additional","affiliation":[{"name":"University of Texas Health Science Center  San Antonio TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert S.","family":"Svatek","sequence":"additional","affiliation":[{"name":"University of Texas Health Science Center  San Antonio TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,11,21]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.07.031"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2009.11.038"},{"key":"e_1_2_7_4_1","first-page":"751","article-title":"Delayed gastric emptying and postoperative ileus after nongastric abdominal surgery: part I","volume":"92","author":"Resnick J","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_7_5_1","first-page":"934","article-title":"Delayed gastric emptying and postoperative ileus after nongastric abdominal surgery: part II","volume":"92","author":"Resnick J","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(01)01561-8"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)64045-1"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.07.018"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000173923.35338.99"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2010.02.053"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamcollsurg.2009.09.028"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100292"},{"key":"e_1_2_7_13_1","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1097\/01.sla.0000141158.27977.66","article-title":"Alvimopan, a novel, peripherally acting mu opioid antagonist: results of a multicenter, randomized, double\u2010blind, placebo\u2010controlled, phase III trial of major abdominal surgery and postoperative ileus","volume":"240","author":"Wolff BG","year":"2004","journal-title":"Ann Surg"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10350-005-0035-7"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00464-005-0104-y"},{"key":"e_1_2_7_16_1","unstructured":"TechnerL.A phase 4 multicenter double\u2010blind placebo\u2010controlled parallel study of alvimopan for the management of postoperative ileus in subjects undergoing radical cystectomy. ClinicalTrialsgov [Internet] Bethesda (MD): National Library of Medicine (US) 2011. Available at:http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00708201. Accessed August 2012"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)65074-4"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2004.01.029"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)65292-5"},{"key":"e_1_2_7_20_1","unstructured":"National Aeronautics and Space Administration (NASA).Gross Domestic Product Deflator Inflation Calculator.2007[Cited 12 March 2012]. Available at:http:\/\/cost.jsc.nasa.gov\/inflategdp.html. Accessed August 2012"},{"key":"e_1_2_7_21_1","volume-title":"National PBM Drug Monograph Alvimopan Monograph","author":"Coombe R","year":"2009"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2009.15.6.485"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.143.11.1098"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03696.x"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamcollsurg.2007.01.041"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp080329"},{"key":"e_1_2_7_27_1","unstructured":"Food and Drug Administration Web site.Meeting of the Gastrointestinal Drugs Advisory Committee (GIDAC) To Evaluate Entereg (Alvimopan) for the Acceleration of Recovery Time to Upper and Lower Gastrointestinal Recovery Following Partial Large or Small Bowel Resection Surgery with Primary Anastomosis.2008. Available at:http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/08\/briefing\/2008\u20104336b1\u201001\u2010fda.pdf. Accessed 20 April 2012"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000138785.48347.aa"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-410X.2012.11499.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-410X.2012.11499.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1464-410X.2012.11499.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T16:20:29Z","timestamp":1761754829000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-410X.2012.11499.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,21]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["10.1111\/j.1464-410X.2012.11499.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1464-410x.2012.11499.x","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,21]]},"assertion":[{"value":"2012-11-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}